Financial Data and Key Metrics Changes - IceCure Medical reported record fourth quarter sales of approximately $1.3 million, leading to total revenue from sales of $3.4 million for the full year ended December 31, 2025, reflecting significant growth driven by unit sales and FDA clearance [5][6][12] Business Line Data and Key Metrics Changes - The growth in sales was attributed to the positive effects of U.S. FDA clearance for ProSense in low-risk early-stage breast cancer and the continued adoption of ProSense in key markets [5][6] - The company is experiencing a clear uptick in interest and engagement from patients and facilities, with expectations to close an increasing number of system sales and installations during the second quarter of 2026 [17][20] Market Data and Key Metrics Changes - The FDA clearance has driven demand in other markets where ProSense already has approval, particularly in Europe, leading to expanded usage for new clinical applications [12][14] - In Canada, the company submitted a Class III amended application to expand regulatory approval for ProSense to include treatment for early-stage, low-risk invasive breast cancer in patients aged 60 and older, potentially impacting around 7,130 women annually [13][38] Company Strategy and Development Direction - IceCure Medical aims to triple its U.S. commercial team by the end of the year to address growing demand and achieve broader market penetration [17][20] - The company is focusing on increasing reimbursement coverage, particularly through the transition to CPT Category I codes, which is expected to spur additional demand and improve reimbursement rates [25][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that the FDA clearance and new medical society guidelines recommending cryoablation for low-risk breast cancer will significantly enhance ProSense's adoption and market presence [6][8] - The company anticipates that the post-marketing study will accelerate the national rollout and availability of ProSense, with patient enrollment expected to commence in late summer [19][20] Other Important Information - IceCure Medical has seen a record number of peer-reviewed publications and conference presentations in 2025, enhancing ProSense's reputation and driving demand for its adoption [15][16] - The company is actively working with medical societies to improve reimbursement processes and expand its market presence [20][25] Q&A Session Summary Question: Plans for reimbursement coverage beyond Medicare - Management is focusing on Medicare Advantage plans and private payers, with a payer outreach program in place to increase coverage [23][25] Question: Impact of CPT-1 code on demand - Management believes that obtaining CPT-1 will improve total reimbursement and serve as a significant inflection point for growth [26] Question: Status of post-market study sites - Management confirmed that high interest has been shown from identified sites, with ongoing work to meet requirements for both clinical and commercial use [30][34] Question: Regulatory approval opportunities in Canada and Japan - The Canadian submission targets patients aged 60 and above, representing over 10,000 new cases annually, while in Japan, collaboration with Terumo is underway for regulatory submission [36][38]

Core Viewpoint - The article highlights the launch of a new generation of targeted cryoablation needles by the company, which features a 1.2mm needle diameter, breaking the traditional limitations of cryoablation technology and setting a new standard for minimally invasive and efficient tumor treatment [2][4]. Group 1: Product Features - The new cryoablation needle utilizes a unique nitrogen Joule-Thomson phase change cooling technology, achieving a 1.2mm ultra-fine needle diameter while maintaining a 3cm ablation diameter [4]. - The device allows for adjustable heating from 40 to 150℃ through PID intelligent temperature control, enabling a balance between minimal invasiveness and sufficient ablation capability [4][5]. - The needle's design significantly reduces the risk of complications such as bleeding and pneumothorax due to its ultra-fine diameter [5]. Group 2: Efficiency and Adaptability - The targeted cryoablation system offers 56 specifications to meet individual clinical needs, including various needle diameters and lengths, allowing for tailored treatment options [6]. - The system achieves rapid cooling to -170℃ within 30 seconds, enhancing the formation of intracellular ice crystals and improving tumor destruction efficiency [7]. - The device features real-time temperature monitoring at the ablation site, providing doctors with better control over the treatment process [7]. Group 3: Operational Improvements - The new cryoablation needle includes enhancements such as a lighter, more flexible delivery tube, improving the puncture experience and accuracy [8]. - Additional features like target area markings and silicone limit rings assist clinicians in managing the core freezing zone and puncture depth effectively [8]. - The device can operate using standard industrial nitrogen as the sole gas source, significantly reducing operational costs to one-tenth of traditional methods [10][13]. Group 4: Company Milestones - The company has achieved significant milestones over the past two decades, including the launch of China's first percutaneous tumor cryoablation system in 2014 and the world's first bronchial cryoablation system in 2024 [10][13]. - The introduction of the 1.2mm cryoablation needle in 2026 marks another breakthrough in the field, pushing the limits of minimally invasive and effective tumor treatment [10][13].

Financial Data and Key Metrics Changes - For the nine months ended September 30, 2025, revenue was $2.1 million, a decrease from $2.4 million in the same period of 2024, primarily due to a lack of revenue from Terumo, the distributor in Japan [16] - Gross profit for the same period was $626,000, down from $1,034,000 in the prior year, resulting in a gross margin of 30% compared to 43% in 2024 [17] - Net loss for the nine months ended September 30, 2025, was $10.8 million or $0.18 per share, relatively unchanged from a net loss of $10 million or $0.22 per share in the same period last year [17] - As of September 30, 2025, cash equivalents and short-term deposits were $10 million, up from $7.6 million at the end of 2024, with a cash balance of $11.8 million as of October 31, 2025 [18] Business Line Data and Key Metrics Changes - The decrease in sales during the nine months ended September 30, 2025, was attributed to declines in Japan, other Asian territories, and North America, partially offset by an increase in Latin America [16] - The company expects fluctuations in quarterly revenue as commercial activities ramp up following the FDA's marketing clearance for ProSense [16] Market Data and Key Metrics Changes - The FDA granted marketing authorization for the ProSense cryoablation system to treat low-risk breast cancer, targeting a population of approximately 200,000 patients annually in the U.S. [6][8] - The ProSense system is expected to benefit from a CPT-3 code covering approximately $3,800 in facility costs, which is anticipated to increase to just over $4,000 in early January 2026 [10] Company Strategy and Development Direction - The company is focused on expanding ProSense installations and utilization in the U.S. and globally, with plans for a post-market study involving 30 clinical sites [9][10] - IceCure aims to drive growth by expanding clinical evidence, improving reimbursement, and entering new markets, particularly in Brazil and Japan [12][15] Management's Comments on Operating Environment and Future Outlook - Management believes the FDA marketing authorization has significantly changed the company's growth trajectory and is optimistic about the future [27] - The company is entering an exciting growth phase, with expectations for increased adoption of ProSense in both clinical and commercial settings [15] Other Important Information - The company has received regulatory approval for its next-generation cryoablation system in Israel and secured a notice of patent allowance for its cryo probe in the U.S. and Japan [12][14] - IceCure is experiencing high global interest from clinicians following the FDA decision, with plans for participation in upcoming medical conferences [12] Q&A Session Summary Question: Status of FDA approval for the post-market study - Management confirmed that the protocol has been submitted to the FDA and they are in communication to finalize it, with expectations for approval by early next year [20][21] Question: Clarification on the addressable patient population - Management elaborated that the addressable market includes approximately 46,000 low-risk patients over 70, 88,000 patients not eligible for surgery, and 63,000 patients with benign tumors, totaling over 200,000 potential patients annually in the U.S. [22][24][25]

Core Viewpoint - Adagio Medical's vCLAS cryoablation system has received FDA breakthrough device designation, marking a significant regulatory milestone in the treatment of ventricular tachycardia (VT) [2][4][5] Group 1: vCLAS System Overview - The vCLAS system is designed to treat drug-resistant, recurrent, and persistent monomorphic ventricular tachycardia in patients with ischemic or non-ischemic structural heart disease [4][5] - It utilizes Adagio's proprietary ultra-low temperature cryoablation (ULTC) technology, which can create deeper and more durable lesions compared to traditional methods, potentially improving the safety and efficacy of VT ablation procedures [4][5][12] - The system consists of a cryoablation console and a vCLAS ablation catheter, which features a 15cm long distal ablation segment with eight 1mm electrodes for intracardiac electrogram recording and identification [7][9] Group 2: Market and Treatment Landscape - The incidence of VT varies among populations and is associated with various factors, including coronary artery disease and certain hereditary heart disease syndromes [6] - The VT treatment market has been growing rapidly, with traditional methods like drug therapy and radiofrequency ablation facing limitations in effectiveness and safety [6] - There is increasing demand for cryoablation technology, which offers advantages such as minimal trauma and quick recovery, leading to an expanding market size in the coming years [6] Group 3: Technological Innovations - Adagio Medical has developed unique technologies such as near-critical nitrogen (NCN) cryoablation, which addresses issues like liquid nitrogen volume expansion and allows for precise control of the ablation range and depth [13][16] - The ultra-low temperature cryoablation (ULTC) technology enables the creation of extensive and continuous lesions in both atria and ventricles during a single ablation cycle [17][19] - The pulse field cryoablation (PFCA) technology combines ULTC and pulse field ablation (PFA) in a single catheter, potentially revolutionizing cardiac treatment by preventing bubble formation and allowing for higher voltage operations [20][23] Group 4: Company Background - Adagio Medical, founded in 2011 and headquartered in California, focuses on developing and commercializing products for arrhythmia treatment using its proprietary ultra-low temperature cryoablation technology [35][36] - The company's product line includes the iCLAS system for atrial fibrillation and the vCLAS system for VT, with ongoing clinical trials and regulatory approvals in Europe and the U.S. [36]

它采用 Adagio 专有的 超低温冷冻消融（ ULTC ）技术 ，与传统方法相比，能够在心脏组织中形成更 深、更持久的损伤，从而有可能提高 VT 消融手术的安全性和有效性。 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 心未来 2025 年 4 月 17 日，冷冻消融设备制造公司 Adagio Medica l ( Nasdaq: ADGM) 宣布其 vCLAS 冻消 融系统 获得 FDA 授予的" 突破性设备 "称号，这是公司和心律失常治疗领域的一个重要监管里程碑。 vCLAS 冻消融系统旨在 治疗缺血性或非缺血性结构性心脏病 患者的 药物难治性、复发性、持续性单形 性 室性心动过速（ VT ） 。 目前， vCL AS 已在欧 洲和特定市场上市，但在美国仍处于研究阶段 ，等待关键的 FULCRUM-VT 研 究完成，该研究正在招募 206 名患者以支持未来的上市前批准申请。 此外， 2024 年 3 月， vCLAS 获得 CE 标志批准，用于治疗单形室性心动速。 2024 年 5 月，该产品 获得了 FDA 的研究设备豁免 (I ...